ANALISIS TERAPI ANTIPSIKOTIK TERHADAP KUALITAS HIDUP PASIEN REHABILITASI NAPZA DI LOKA REHABILITASI BADAN NARKOTIKA NASIONAL BATAM

I Gusti Ngurah Agung Artawijaya; Nahrul Hasan; Diani Mega Sari; Ayu Amelia; Ghalib Syukrillah Syahputra

doi:10.36805/sgmf8w86

Authors

I Gusti Ngurah Agung Artawijaya Program Studi Sarjana Farmasi, Institut Kesehatan Mitra Bunda, Batam, Indonesia
Nahrul Hasan Jurusan Farmasi, Universitas Jenderal Soedirman, Purwokerto, Indonesia , Research Centre of Rural Health, Universitas Jenderal Soedirman, Purwokerto, Indonesia
Diani Mega Sari Program Studi Sarjana Farmasi, Institut Kesehatan Mitra Bunda, Batam, Indonesia.
Ayu Amelia Program Studi Pendidikan Profesi Apoteker, Institut Kesehatan Mitra Bunda, Batam, Indonesia
Ghalib Syukrillah Syahputra Program Studi Sarjana Farmasi, Institut Kesehatan Mitra Bunda, Batam, Indonesia.

DOI:

https://doi.org/10.36805/sgmf8w86

Keywords:

Quality of Life, Antipsychotic Therapy, Drug Rehabilitation

Abstract

Antipsychotic therapy is often administered to NAPZA rehabilitation patients with comorbid mental disorders such as schizophrenia, bipolar disorder, or major depression. This study aims to analyze the effect of antipsychotic therapy on the quality of life of NAPZA rehabilitation patients at the BNN Batam Rehabilitation Center. The research method used total sampling with a sample size of 26 respondents. Quality of life was measured using the WHOQOL-BREF questionnaire. The results showed that the majority of respondents were male (92.3%) aged 18–49 years, with the most common diagnosis being paranoid schizophrenia (84.6%). The dominant therapy given was second-generation antipsychotics (92.3%). There was an increase in the average quality of life score across all domains, from 58.68 to 73.72 after therapy. The paired t-test showed a significant difference between quality of life before and after therapy (p = 0.000). However, the chi-square test showed no significant relationship between type of therapy and duration of rehabilitation with improvement in quality of life (p ≥ 0.05). In conclusion, antipsychotic therapy significantly improves the quality of life of NAPZA rehabilitation patients.

References

Badan Narkotika Nasional. (2023). Indonesia Drug Report. National Narcotics Board.

Brissos, S., Balanzá-Martinez, V., Dias, V. V., Carita, A. I., & Figueira, M. L. (2011). Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community? European Archives of Psychiatry and Clinical Neuroscience, 261(7), 509–517.

Hofer, A., Mizuno, Y., Wartelsteiner, F., Wolfgang Fleischhacker, W., Frajo-Apor, B., Kemmler, G., Mimura, M., Pardeller, S., Sondermann, C., Suzuki, T., Welte, A., & Uchida, H. (2017). Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. European Psychiatry, 46, 42–47.

Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012). Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors, 37(1), 11–24.

Krause, M., Gutsmiedl, K., Bighelli, I., Schneider-Thoma, J., Chaimani, A., & Leucht, S. (2019). Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. European Neuropsychopharmacology, 29(9), 1003–1022.

Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951–962.

Mardiyah, A., Dupai, L., Prasetya, F., Kesehatan, F., Universitas, M., & Oleo, H. (2018). Studi Kualitatif Kualitas Hidup Mantan Pecandu Narkoba Di Klinik Rehabilitasi Bnn (Badan Narkotika Nasional) Kota Kendari Tahun 2017. In Januari (Vol. 3, Issue 1).

Mueser, K. T., Noordsy, D. L., Drake, R. E., & Smith, L. F. (2015). Integrated Treatment for Dual Disorders: A Guide to Effective Practice. Guilford Publications. https://books.google.co.id/books?id=mOFyCQAAQBAJ

Ova, S. M., & Pratiwi, A. N. (2021). Kualitas Hidup Klien Penyalahguna Narkotika Di Bnn Provinsi Jambi Pada Masa Pandemi Covid-19 Quality Of Life Outpatient Clients In Bnn Of Jambi Province During Covid-19 Pandemic.

Skevington, S. M., Lotfy, M., & O’Connell, K. A. (2004). The World Health Organization’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Quality of Life Research, 13(2), 299–310.

Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic Advances from the Brain Disease Model of Addiction. New England Journal of Medicine, 374(4), 363–371.

World Health Organization. (2018). The World Health Organization Quality of Life (WHOQOL).

Yıldız, M. (2021). Psychosocial rehabilitation interventions in the treatment of schizophrenia and bipolar disorder. Archives of Neuropsychiatry.

Zhornitsky, S., Rizkallah, É., Pampoulova, T., Chiasson, J.-P., Stip, E., Rompré, P.-P., & Potvin, S. (2010). Antipsychotic Agents for the Treatment of Substance Use Disorders in Patients With and Without Comorbid Psychosis. Journal of Clinical Psychopharmacology, 30(4), 417–424.